Barclays
ALLR icon

Barclays’s Allarity Therapeutics ALLR Stock Holding History

Barclays’s Portfolio ALLR Stock Details ALLR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3 Buy
+3
New +$4 ﹤0.01% 5270
2025
Q2 		– Sell
-10,078
Closed -$9.44K – 5233
2025
Q1 		$9.44K Buy
+10,078
New +$10.4K ﹤0.01% 4874
2022
Q4 		– Hold
0
– -$18K – 5262
2022
Q3 		– Hold
0
– – – 4089

Other funds holding ALLR

Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $96.6B AUM 22.52% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
StoneX Group
StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return
Danske Bank
Danske Bank Copenhagen K, Denmark $50.1B AUM 35.17% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $273B AUM 15.34% 1-Year Est. Return

Barclays's ALLR Position: Q3 2026 in Review

Barclays opened a new position in Allarity Therapeutics (ALLR) in Q3 2026: 3 shares worth $3. The stake represents ﹤0.01% of the portfolio and ranks #5270 among its holdings. This is a return to the name: Barclays previously reported a position in ALLR as recently as Q1 2025.

Barclays first reported a position in ALLR in Q1 2025 and has held it in 2 quarters since. The position peaked at $9.44K in Q1 2025. 11 funds tracked by Wall St. Rank hold ALLR as of Q3 2026.

  • Barclays held 3 shares of Allarity Therapeutics worth $3 as of Q3 2026.
  • Allarity Therapeutics was a new Barclays position in Q3 2026.
  • Allarity Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #5270 holding.
  • Barclays first reported a position in Allarity Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • Barclays's Allarity Therapeutics position peaked at $9.44K in Q1 2025.
  • 11 funds tracked by Wall St. Rank held Allarity Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.